Skip to content

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Gene expression analysis after BTK and PI3Kδ inhibitor treatment in chronic lymphocytic leukemia identifies cell‐surface CXCR4 as a synergistic target for combinatorial therapy

BTKi are preferred in clinical practice over idelalisib due to lower toxicity, but idelalisib plus anti ‐ CD20 antibodies remains relevant in the treatment of CLL cases resistant to BTKi and vene-toclax, in BTKi ‐ intolerant patients, and next ‐ generation PI3Ki such as duvelisib or umbralisib are being developed.

Gabriela Mladonicka Pavlasova, Veronika Šandová, L. Ondrišová et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.